Impedimed Ltd (ASX:IPD)
A$ 0.053 0 (0%) Market Cap: 107.22 Mil Enterprise Value: 83.73 Mil PE Ratio: 0 PB Ratio: 2.65 GF Score: 0/100

ImpediMed Limited - Special Call Transcript

Nov 29, 2020 / 10:00PM GMT
Operator

Thank you for standing by, and welcome to the ImpediMed Investor Update Meta-Analysis Publication. (Operator Instructions).

I would now like to hand the conference over to Mr. Richard Carreon, Managing Director and CEO. Please go ahead.

Richard Carreon
ImpediMed Limited - MD, CEO, President & Executive Director

Thank you, Amanda. Good morning, and thank you for joining us this morning. This call is to discuss the meta-analysis that was published this weekend in Breast Cancer Research and Treatment journal.

With me today are Cathy Kingsford, our Senior VP of Clinical and Regulatory; and the lead author of the meta-analysis, Dr. Chirag Shah.

Before I turn the call over to Dr. Shah, let me provide you a summary of his impressive background. Dr. Shah is the associate staff in the Department of Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology, the world-famous Cleveland Clinic. Dr. Shah received his Bachelor's degree from Youngstown State University and his medical degree from Northeast

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot